ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Earnings for ImmunoGen, Inc. (IMGN)
Earnings in 2022 (TTM): $-221,711,000
According to ImmunoGen, Inc.'s latest financial reports the company's current earnings (TTM) are $-221,711,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of ImmunoGen, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-221,711,000 | $-222,929,000 |
| 2021 | $-221,711,000 | $-222,929,000 |
| 2020 | $-44,372,000 | $-66,683,000 |
| 2019 | $-104,133,000 | $-122,093,000 |
| 2018 | $-167,873,000 | $-167,873,000 |
| 2017 | $-96,012,000 | $-96,012,000 |
| 2016 | $-156,733,000 | $-156,733,000 |
| 2015 | $-143,655,000 | $-143,655,000 |
| 2014 | $-60,739,000 | $-60,739,000 |
| 2013 | $-71,364,000 | $-71,364,000 |
| 2012 | $-72,811,000 | $-72,811,000 |
| 2011 | $-73,319,000 | $-73,319,000 |
| 2010 | $-58,274,000 | $-58,274,000 |
| 2009 | $-51,177,000 | $-50,912,000 |
| 2008 | $-32,037,000 | $-31,937,000 |
| 2007 | $-31,993,000 | $-32,020,000 |
| 2006 | $-18,953,000 | $-18,987,000 |
| 2005 | $-17,817,000 | $-17,834,000 |
| 2004 | $-10,922,000 | $-10,951,000 |
| 2003 | $-5,871,741 | $-5,916,741 |
| 2002 | $-19,947,183 | $-19,982,308 |
| 2001 | $-14,502,027 | $-14,629,839 |
| 2000 | $-9,473,604 | $-15,290,682 |
| 1999 | $-237,560 | $-237,560 |
| 1998 | $-4,100,000 | $-4,100,000 |
| 1997 | $-7,600,000 | $-7,600,000 |
| 1996 | $-9,000,000 | $-9,000,000 |
| 1995 | $-16,500,000 | $-16,500,000 |
| 1994 | $-19,900,000 | $-19,900,000 |
| 1993 | $-23,700,000 | $-23,700,000 |
| 1992 | $-18,600,000 | $-18,600,000 |
| 1991 | $-15,300,000 | $-15,300,000 |
| 1990 | $-8,700,000 | $-8,800,000 |
| 1989 | $-8,300,000 | $-8,300,000 |
| 1988 | $-5,300,000 | $-5,300,000 |